Compare Aurobindo Pharma with Piramal Healthcare - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs PIRAMAL ENTERPRISES - Comparison Results

AUROBINDO PHARMA     Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

PIRAMAL ENTERPRISES 
   Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA PIRAMAL ENTERPRISES AUROBINDO PHARMA/
PIRAMAL ENTERPRISES
 
P/E (TTM) x 19.2 17.6 109.1% View Chart
P/BV x 3.9 1.2 325.1% View Chart
Dividend Yield % 0.3 1.9 14.0%  

Financials

 AUROBINDO PHARMA   PIRAMAL ENTERPRISES
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-19
PIRAMAL ENTERPRISES
Mar-19
AUROBINDO PHARMA/
PIRAMAL ENTERPRISES
5-Yr Chart
Click to enlarge
High Rs8303,303 25.1%   
Low Rs5271,797 29.3%   
Sales per share (Unadj.) Rs333.9716.5 46.6%  
Earnings per share (Unadj.) Rs40.479.7 50.6%  
Cash flow per share (Unadj.) Rs51.8107.9 48.0%  
Dividends per share (Unadj.) Rs2.5028.00 8.9%  
Dividend yield (eoy) %0.41.1 33.5%  
Book value per share (Unadj.) Rs237.11,477.5 16.0%  
Shares outstanding (eoy) m585.91184.45 317.7%   
Bonus/Rights/Conversions ESOPIS-  
Price / Sales ratio x2.03.6 57.1%   
Avg P/E ratio x16.832.0 52.6%  
P/CF ratio (eoy) x13.123.6 55.5%  
Price / Book Value ratio x2.91.7 165.9%  
Dividend payout %6.235.1 17.6%   
Avg Mkt Cap Rs m397,569470,292 84.5%   
No. of employees `00017.97.8 228.3%   
Total wages/salary Rs m25,84922,504 114.9%   
Avg. sales/employee Rs Th10,956.916,899.4 64.8%   
Avg. wages/employee Rs Th1,447.72,877.7 50.3%   
Avg. net profit/employee Rs Th1,324.31,879.9 70.4%   
INCOME DATA
Net Sales Rs m195,636132,153 148.0%  
Other income Rs m1,5533,128 49.7%   
Total revenues Rs m197,189135,281 145.8%   
Gross profit Rs m39,51966,290 59.6%  
Depreciation Rs m6,6805,202 128.4%   
Interest Rs m2,62644,097 6.0%   
Profit before tax Rs m31,76720,119 157.9%   
Minority Interest Rs m273,194 0.8%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-8810-   
Tax Rs m7,2698,611 84.4%   
Profit after tax Rs m23,64514,701 160.8%  
Gross profit margin %20.250.2 40.3%  
Effective tax rate %22.942.8 53.5%   
Net profit margin %12.111.1 108.6%  
BALANCE SHEET DATA
Current assets Rs m153,645122,742 125.2%   
Current liabilities Rs m120,429310,810 38.7%   
Net working cap to sales %17.0-142.3 -11.9%  
Current ratio x1.30.4 323.1%  
Inventory Days Days13523 586.1%  
Debtors Days Days6439 164.0%  
Net fixed assets Rs m103,909116,904 88.9%   
Share capital Rs m586369 158.8%   
"Free" reserves Rs m138,322272,161 50.8%   
Net worth Rs m138,908272,530 51.0%   
Long term debt Rs m1,800270,196 0.7%   
Total assets Rs m264,544856,261 30.9%  
Interest coverage x13.11.5 899.4%   
Debt to equity ratio x01.0 1.3%  
Sales to assets ratio x0.70.2 479.2%   
Return on assets %9.96.9 144.6%  
Return on equity %17.05.4 315.6%  
Return on capital %23.812.4 191.9%  
Exports to sales %49.60-   
Imports to sales %18.80-   
Exports (fob) Rs m97,091NA-   
Imports (cif) Rs m36,741NA-   
Fx inflow Rs m97,31615,200 640.2%   
Fx outflow Rs m40,5894,889 830.2%   
Net fx Rs m56,72710,312 550.1%   
CASH FLOW
From Operations Rs m16,220-115,975 -14.0%  
From Investments Rs m-28,768-8,265 348.1%  
From Financial Activity Rs m19,191107,525 17.8%  
Net Cashflow Rs m6,656-16,650 -40.0%  

Share Holding

Indian Promoters % 54.1 52.9 102.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.0 4.0 198.8%  
FIIs % 27.7 26.6 104.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.2 16.5 61.8%  
Shareholders   69,601 93,274 74.6%  
Pledged promoter(s) holding % 8.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   DR. REDDYS LAB  STERLING BIOTECH  JUBILANT LIFE SCIENCES  VENUS REMEDIES  IPCA LABS  

Compare AUROBINDO PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Flat; Healthcare and Metal Stocks Witness Selling(Closing)

After staging a gap-down opening, Indian share markets recovered losses as the session progressed and ended on a flat note.

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (4QFY20); Net Profit Up 48.2% (Quarterly Result Update)

Jun 5, 2020 | Updated on Jun 5, 2020

For the quarter ended March 2020, AUROBINDO PHARMA has posted a net profit of Rs 9 bn (up 48.2% YoY). Sales on the other hand came in at Rs 62 bn (up 16.4% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 0.5% (Quarterly Result Update)

Feb 7, 2020 | Updated on Feb 7, 2020

For the quarter ended December 2019, AUROBINDO PHARMA has posted a net profit of Rs 7 bn (down 0.5% YoY). Sales on the other hand came in at Rs 58 bn (up 10.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

PIRAMAL ENTERPRISES Announces Quarterly Results (3QFY20); Net Profit Up 11.7% (Quarterly Result Update)

Feb 5, 2020 | Updated on Feb 5, 2020

For the quarter ended December 2019, PIRAMAL ENTERPRISES has posted a net profit of Rs 6 bn (up 11.7% YoY). Sales on the other hand came in at Rs 38 bn (up 9.1% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 4.6% (Quarterly Result Update)

Nov 15, 2019 | Updated on Nov 15, 2019

For the quarter ended September 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 4.6% YoY). Sales on the other hand came in at Rs 56 bn (up 17.9% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Nov 6, 2019 | Updated on Nov 6, 2019

Here's an analysis of the annual report of AUROBINDO PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of AUROBINDO PHARMA. Also includes updates on the valuation of AUROBINDO PHARMA.

More Views on News

Most Popular

Large Opportunities Are Coming Our Way

Aug 5, 2020

Kenneth Andrade tells us why stocks will bounce back strongly and what he's bullish on.

Is It Time to Book Profits in Gold and Silver?(Fast Profits Daily)

Aug 10, 2020

Gold and silver have delivered phenomenal returns this year. Is it time to take some money of the table?

Forget the Nifty and Sensex for the Next 1 or 2 Years and Focus on These Stocks(Profit Hunter)

Aug 6, 2020

Stocks from the essential small cap space are likely to be outperformers over the next 1 or 2 years.

This 20 Year Cycle Suggests Gold is Set for an August Rally(Profit Hunter)

Jul 31, 2020

The real reason why gold prices will go up more.

More

Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Aug 12, 2020 (Close)

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA - STRIDES PHARMA SCIENCE COMPARISON

COMPARE AUROBINDO PHARMA WITH

MARKET STATS